Sinopharm Tech Holdings Limited

DB:YB2 Stock Report

Market Cap: €3.2m

Sinopharm Tech Holdings Past Earnings Performance

Past criteria checks 0/6

Sinopharm Tech Holdings's earnings have been declining at an average annual rate of -4.1%, while the Hospitality industry saw earnings declining at 8.8% annually. Revenues have been declining at an average rate of 4.4% per year.

Key information

-4.1%

Earnings growth rate

1.2%

EPS growth rate

Hospitality Industry Growth-11.8%
Revenue growth rate-4.4%
Return on equityn/a
Net Margin-24.8%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sinopharm Tech Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:YB2 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2343-11970
31 Mar 2323-55570
31 Dec 2244-59620
30 Sep 2245-74680
30 Jun 2241-88760
31 Mar 2248-98640
31 Dec 2134-106700
30 Sep 2133-111730
30 Jun 2178-106750
31 Mar 21136-160690
31 Dec 20134-158680
30 Sep 20161-162720
30 Jun 20166-161710
31 Mar 20120-49620
31 Dec 19119-45670
30 Sep 1989-38560
30 Jun 1944-47580
31 Mar 1928-42750
31 Dec 1825-49760
30 Sep 1824-58850
30 Jun 1825-61900
31 Mar 1822-1561080
31 Dec 1724-1641190
30 Sep 1725-1721300
30 Jun 1726-1751340
31 Mar 1732-2231690
31 Dec 1629-2221650
30 Sep 1626-2181600
30 Jun 1635-2071590
31 Mar 1627-631010
31 Dec 1578-22990
30 Sep 151218980
30 Jun 1512419950
31 Mar 1513537850
31 Dec 1413136790
30 Sep 1410325730
30 Jun 149615680
31 Mar 1490-11700
31 Dec 1352-20670
30 Sep 1342-36690
30 Jun 1339-42710
31 Mar 1358-1,116810
31 Dec 1267-1,128860

Quality Earnings: YB2 is currently unprofitable.

Growing Profit Margin: YB2 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: YB2 is unprofitable, and losses have increased over the past 5 years at a rate of 4.1% per year.

Accelerating Growth: Unable to compare YB2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YB2 is unprofitable, making it difficult to compare its past year earnings growth to the Hospitality industry (18.1%).


Return on Equity

High ROE: YB2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/09 09:44
End of Day Share Price 2023/09/13 00:00
Earnings2023/06/30
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sinopharm Tech Holdings Limited is covered by 2 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hoi Yin YipEverbright Securities International (HK) Limited (“EBSIHK”)
Hua HeIndustrial Securities (HK) Financial Holdings